Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma

Ann‐Lii Cheng; Chiun Hsu; Stephen L. Chan; Su Pin Choo; Masatoshi Kudo

doi:10.1016/j.jhep.2019.09.025

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2020

Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma

Naoshi Nishida, Masatoshi Kudo

Editorial Material2024

Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma

Masatoshi Kudo

Article2023

Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma

Enrui Xie, Yee Hui Yeo, Bernhard Scheiner, Yue Zhang, Atsushi Hiraoka, Xinxing Tantai, Petros Fessas, Tiago B. R. Castro, Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Shuo Xu, Hong‐Ming Tsai, Swetha Kambhampati, Wenjun Wang, Bridget P. Keenan, Xu Gao, Zixuan Xing, Matthias Pinter, Yih‐Jyh Lin, Zhanjun Guo, Arndt Vogel, Takaaki Tanaka, Hsin‐Yu Kuo, Robin Kate Kelley, Masatoshi Kudo, Ju Dong Yang, David J. Pinato, Fanpu Ji

Letter2020

Promising anticancer therapy: combination of immune checkpoint inhibitors and molecular-targeted agents

Toshiharu Sakurai, Naoshi Nishida, Masatoshi Kudo

Article2024

Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors

Linda Y. Wu, Sarah Cappuyns, Amanda S. Loh, Sean Sun, Sara Lewis, Max W. Sung, Myron Schwartz, Josep M. Llovet, Deirdre Jill Cohen

BJC Reports